5 Key Takeaways

• 1

  CANDI combines broad-range DNA amplification with species-specific CRISPR recognition to identify 15 clinically relevant mycobacterial species within hours.

• 2

  The platform uses fluorescently labeled nanodroplets to identify multiple mycobacterial species simultaneously.

• 3

  In evaluation, CANDI identified mixtures of up to five species, including closely related organisms in the Mycobacterium abscessus and Mycobacterium avium complexes.

• 4

  Clinical testing showed high agreement with culture-based identification, and CANDI detected some organisms missed by conventional methods.

• 5

  Molecular detection cannot distinguish active infection from colonization, and manual workflow steps and the need for further validation remain barriers to routine use.